Pulmonology · Medical Literature
Systematic Review and Meta-analysis of Interactive Digital Self-management Interventions for Adults with Chronic Respiratory Disease in Randomized Controlled Trials.
Abstract
Interactive digital self-management (IDSM) interventions may help individuals with chronic respiratory disease self-manage their condition. This review aimed to summarize the characteristics and effectiveness of IDSM interventions for this population. Reviewers systematically screened titles, abstracts, and full texts of randomized controlled trials (RCTs) examining applications or wearable devices for IDSM in adults with chronic respiratory diseases. Study and intervention characteristics and outcomes were extracted. Meta-analysis was conducted in a subset of studies. The search generated 109,900 unique records and 34 relevant RCTs were identified. These studies evaluated 2,320 individuals with asthma, 1,766 with chronic obstructive pulmonary disease (COPD; FEV1 % predicted 36 to 69), and 33 with cystic fibrosis. In asthma, median (range) intervention length was 12 (1-52) weeks. In COPD, median (range) intervention length was 24 (2-48) weeks. In COPD, IDSM interventions showed greater effect than control for health status (COPD Assessment Test score mean difference [95% CI]: -1.6 [-3.2, 0.0], p < 0.05, very low quality of evidence), physical activity (steps per day: 937.9 [95% CI: 311.5, 1,564.4], p < 0.05, very low quality of evidence), and exercise capacity (six-minute walk test distance mean difference [95% CI]: 5.6 [1.7, 9.4], p < 0.05, low quality of evidence). In asthma, no statistically significant effect was observed for asthma control or quality of life and only one RCT in cystic fibrosis was identified. Interventions were heterogeneous and yielded very low to moderate quality evidence. In COPD, IDSM interventions were associated with statistically significant improvements in health status, physical activity, and exercise capacity; however, findings should be interpreted cautiously due to low or very low certainty of evidence. Evidence in asthma and cystic fibrosis remains limited and inconsistent. At present, IDSM tools should be considered adjunctive options rather than replacements for established self-management strategies.
Clinical relevance
In adults with chronic respiratory disease (asthma, COPD, or cystic fibrosis), do interactive digital self-management interventions delivered via applications or wearable devices improve health status, physical activity, and other patient-important outcomes compared to control conditions in randomized controlled trials? __SNAPSHOT__ {"studyDesign":"Systematic review with meta-analysis of randomized controlled trials","setting":"International; multi-setting (included studies not restricted to a single country or institution type); conducted at West Park Healthcare Centre and University of Toronto, Canada","sampleSize":"34 RCTs included; n=4,119 participants total (asthma: n=2,320; COPD: n=1,766; cystic fibrosis: n=33); meta-analysis conducted in a subset of studies","population":"Adults with chronic respiratory disease: asthma, COPD (FEV1% predicted range 36–69% across included studies), or cystic fibrosis; specific inclusion criteria varied by individual trial","intervention":"Interactive digital self-management (IDSM) interventions delivered via mobile/web applications or wearable devices","comparator":"Control conditions (nature of comparators varied across trials; e.g., usual care, passive education, sham app); specific comparator types not uniformly reported in the abstract","primaryOutcome":"No single pre-specified primary outcome for the review; key pooled outcomes included health status (COPD Assessment Test [CAT] score), physical activity (steps per day), and others not fully reported in the available abstract","followUp":"Asthma studies: median 12 weeks (range 1–52 weeks); COPD studies: median 24 weeks (range 2–48 weeks); cystic fibrosis: not reported","fundingSource":"Not reported in the available abstract"}
Key findings
The systematic search yielded 109,900 unique records, with 34 RCTs meeting inclusion criteria. Populations included 2,320 individuals with asthma, 1,766 with COPD (FEV1% predicted 36–69%), and 33 with cystic fibrosis. For COPD, IDSM interventions demonstrated a statistically significant but marginal improvement in health status as measured by the COPD Assessment Test (CAT): mean difference −1.6 points (95% CI: −3.2 to 0.0, p<0.05), rated as very low quality of evidence. The MCID for CAT is generally accepted as 2 points; the observed mean difference of −1.6 points falls below this threshold, raising questions about clinical importance independent of statistical significance. The absolute lower bound of the confidence interval (−3.2) only marginally crosses the commonly accepted MCID. Physical activity outcomes (steps per day for COPD) were also reported as favoring IDSM, but the full quantitative results for this and all additional outcomes (e.g., asthma outcomes, exacerbations, quality of life, healthcare utilization) were not available in the truncated abstract provided and are therefore not reported here. The cystic fibrosis sample (n=33 across included trials) was too small to support meaningful meta-analysis. NNT could not be calculated from the data provided.
Practice implications
This review established that IDSM interventions for COPD are associated with a statistically significant improvement in health status (CAT score) compared to control, but the magnitude of effect (MD −1.6 points) falls below the commonly accepted MCID of 2 points, limiting confidence in clinical meaningfulness. The very low quality of evidence rating (likely reflecting GRADE assessment) further constrains any strong practice recommendations. The findings are most applicable to adults with moderate-to-severe COPD (FEV1% predicted 36–69%) who have access to digital health platforms. Results in asthma and cystic fibrosis are incompletely reported in the available abstract, and the cystic fibrosis cohort (n=33 total) is far too small to draw generalizable conclusions. Populations with limited digital literacy, low socioeconomic status, or significant comorbidities were likely underrepresented in the underlying trials. Importantly, this summary is based solely on the published abstract; full-text review is required to evaluate heterogeneity statistics, risk-of-bias assessments, subgroup analyses, adverse events, and the complete results for asthma and all secondary outcomes. Practice change is not supported at this time based on the available data alone. __LIMITATIONS__ Evidence quality rated as very low for the primary COPD health status outcome, substantially limiting confidence in the pooled estimates.,The mean CAT improvement (−1.6 points) falls below the accepted MCID of 2 points; statistical significance does not confirm clinical importance.,Marked heterogeneity is anticipated across 34 trials given diverse app types, control conditions, disease severity, outcome measures, and follow-up durations; I² statistics not available in the abstract.,Cystic fibrosis subsample (n=33) is critically underpowered and precludes meaningful inference.,Median follow-up in COPD (24 weeks) and asthma (12 weeks) is insufficient to assess durability of effects, adherence trajectories, or impact on exacerbation rates and hospitalization.,Control group heterogeneity (usual care vs. active comparator vs. sham app) could substantially distort pooled effect estimates.,Potential for publication bias given the large initial record count (109,900) yielding only 34 eligible RCTs.,Generalizability may be limited by underrepresentation of older adults, individuals with low digital literacy, non-English-speaking populations, and low-resource settings.,Funding sources for the included trials were not reported in the abstract, precluding assessment of industry sponsorship bias.,Only the abstract was available for this summary; full quantitative results for asthma outcomes, physical activity, exacerbations, and all secondary endpoints could not be reviewed. __BOTTOM_LINE_CATEGORY__ promising_but_preliminary __BOTTOM_LINE__ IDSM interventions in COPD showed a statistically significant but likely sub-clinically meaningful improvement in CAT health status score (MD −1.6 points, 95% CI −3.2 to 0.0; very low quality of evidence), with physical activity benefits also reported but not fully quantifiable from the available abstract. The extremely small cystic fibrosis sample and variable asthma outcomes preclude broad conclusions across chronic respiratory diseases. Routine clinical adoption of IDSM tools cannot be justified on this evidence alone; larger, higher-quality RCTs with longer follow-up and standardized outcomes are needed before practice-level recommendations can be made.